In a clinical trial of renal cell carcinoma patients treated with anti-PD1 or anti-PD-L1 alone, or in combination with anti-CTLA4, PBRM1 mutation is related with a higher ORR and longer survival (18). This evidence concerns the gene CTLA4 and renal cell carcinoma.